Tafamidis binding site occupancy and transthyretin stabilization in ATTR-CM
In this learning journey you will:
- Explore the mechanism of disease of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Deep dive into the mechanism of action of Tafamidis in ATTR-CM
- Recognize the importance of the characterization of Tafamidis as a selective stabilizer of TTR
- Understand the importance and implications of timely treatment for patients with ATTR-CM
- Review modeling data that supports TTR stabilization as a clinically effective method of treatment for ATTR-CM
Home page journey desciption
Venous thromboembolism is a leading cause of death in patients with cancer.
Khorana AA et al. J Thromb Haemost. 2007;5:632-634
Reference
1. Khorana AA et al. J Thromb Haemost. 2007;5:632-634
2. Agnelli G et al. N Engl J Med. 2020;382:1599-1607.
